145 related articles for article (PubMed ID: 17018892)
1. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.
Díaz R; Aparicio J; Molina J; Palomar L; Giménez A; Ponce J; Segura A; Gómez-Codina J
Med Oncol; 2006; 23(3):347-57. PubMed ID: 17018892
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Aparicio T; Desramé J; Lecomte T; Mitry E; Belloc J; Etienney I; Montembault S; Vayre L; Locher C; Ezenfis J; Artru P; Mabro M; Dominguez S;
Br J Cancer; 2003 Oct; 89(8):1439-44. PubMed ID: 14562014
[TBL] [Abstract][Full Text] [Related]
6. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
8. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Chibaudel B; Bonnetain F; Tournigand C; Bengrine-Lefevre L; Teixeira L; Artru P; Desramé J; Larsen AK; André T; Louvet C; de Gramont A
Oncologist; 2011; 16(9):1228-38. PubMed ID: 21859820
[TBL] [Abstract][Full Text] [Related]
9. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
[TBL] [Abstract][Full Text] [Related]
10. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
[TBL] [Abstract][Full Text] [Related]
11. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Catalano V; Loupakis F; Graziano F; Torresi U; Bisonni R; Mari D; Fornaro L; Baldelli AM; Giordani P; Rossi D; Alessandroni P; Giustini L; Silva RR; Falcone A; D'Emidio S; Fedeli SL
Br J Cancer; 2009 Mar; 100(6):881-7. PubMed ID: 19259089
[TBL] [Abstract][Full Text] [Related]
12. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
[TBL] [Abstract][Full Text] [Related]
14. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
15. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
Jansman FG; Idzinga FS; Smit WM; de Graaf JC; Coenen JL; Sleijfer DT; Brouwers JR
Clin Ther; 2005 Mar; 27(3):327-35. PubMed ID: 15878386
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
Hoff PM; Wolff RA; Xiong H; Jones D; Lin E; Eng C; Dutta A; Bogaard KR; Abbruzzese JL
Cancer; 2006 May; 106(10):2241-6. PubMed ID: 16598762
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
[TBL] [Abstract][Full Text] [Related]
20. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]